Physician profile

Daniel Neuzil

Vascular Surgery · Baltimore, MD

NPI 1366455651

$1,932.11

in general payments reported to CMS, 2019-2025

9 companies · none reported in 2025

Payments by year

General payments by program year, as reported to CMS.

What the payments were for

Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.

View as a table
Payment typeAmount (2023-2025)
Food and Beverage$147.70

Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.

Who reported paying

General payments only, as reported to CMS. Product names cover 2023-2025.

CompanyGeneral paymentsYearsTop products
Silk Road Medical, INC. $894.39 2019-2022
W. L. Gore & Associates, INC. $473.76 2019-2023 Gore Viabahn Vbx Balloon Expandable Endo
Medtronic, INC. $149.25 2022
Cook Medical LLC $118.36 2019-2023 Zilver Ptx
Shockwave Medical, INC $110.97 2022
Medtronic Vascular, INC. $74.23 2019
Bard Peripheral Vascular, INC. $73.43 2019
Boston Scientific Corporation $23.13 2023
Astellas Pharma US INC $14.59 2019

Drugs and devices associated with these payments

CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.

If you want to bring it up

Most clinicians are glad to talk about this. A respectful way in:

These are normal questions. A good clinician will welcome them.

Share this page

Payment summary

Daniel Neuzil

$1,932.11

in general payments reported 2019-2025

Years
2019-2023
Top company
Silk Road Medical, INC.

https://glasscript.com/doctor/243742/daniel-neuzil

Source: CMS Open Payments, program years 2019-2025. Payments are legal and often routine.

Keep an eye on this page

Get an email when the next June refresh changes this page. No account needed.

Watch this doctor

Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.